Fresenius SE & Co KGaA - Bad Homburg, Germany-based health care company - Says Fresenius Kabi's tocilizumab biosimilar candidate, MSB11456, has received a positive recommendation for a marketing authorization from the European Medicines Agency's committee for medicinal products for human use. Says MSB11456 becomes the first tocilizumab biosimilar candidate to be granted a positive opinion by the CHMP for the treatment of several autoimmune diseases.
"This achievement marks a significant milestone in Fresenius Kabi's Vision 2026 growth strategy," it adds.
Current stock price: EUR28.27, up 0.5% in Frankfurt on Friday afternoon
12-month change: up 5.0%
By Sophie Rose, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.